These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 28767619)

  • 1. Women Administered Standard Dose Imatinib for Chronic Myeloid Leukemia Have Higher Dose-Adjusted Plasma Imatinib and Norimatinib Concentrations Than Men.
    Belsey SL; Ireland R; Lang K; Kizilors A; Ho A; Mufti GJ; Bisquera A; De Lavallade H; Flanagan RJ
    Ther Drug Monit; 2017 Oct; 39(5):499-504. PubMed ID: 28767619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First report of imatinib measurement in hair: Method development and preliminary evaluation of the relation between hair and plasma concentrations with therapeutic response in chronic myeloid leukemia.
    Capron A; Antunes MV; Wagner SC; Mattevi VS; Vieira N; Leite R; Reginato F; Capra M; Fogliatto L; Wallemacq P; Linden R
    Clin Chim Acta; 2016 Jan; 453():42-7. PubMed ID: 26657979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Imatinib Concentrations in Samples Submitted for BCR-ABL1 or Imatinib Testing-Evidence to Support Therapeutic Drug Monitoring for Dose Optimization?
    Smy L; Sadler AJ; McMillin GA
    Ther Drug Monit; 2020 Aug; 42(4):559-564. PubMed ID: 32697563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia].
    Zhong JS; Meng FY; Xu D; Zhou HS; Dai M
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):177-82. PubMed ID: 22781602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study.
    Van Obbergh F; Knoops L; Devos T; Beguin Y; Graux C; Benghiat F; Kargar-Samani K; Bauwens D; Efira A; Dubois C; Springael C; Montfort L; Connerotte T; Capron A; Delannoy A; Wallemacq P
    Clin Biochem; 2017 May; 50(7-8):452-454. PubMed ID: 28017570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study.
    Ostojic A; Sertic D; Roncevic P; Peric Z; Granic P; Matic N; Basic-Kinda S; Serventi-Seiwerth R; Radman I; Zadro R; Nemet D
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):472-6. PubMed ID: 27245313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor.
    Gómez-Sámano MÁ; Baquerizo-Burgos JE; Coronel MFC; Wong-Campoverde BD; Villanueva-Martinez F; Molina-Botello D; Avila-Rojo JA; Palacios-Báez L; Cuevas-Ramos D; Gomez-Perez FJ; Zentella-Dehesa A; Aguayo-González Á; Gulias-Herrero A
    BMC Endocr Disord; 2018 Nov; 18(1):77. PubMed ID: 30390651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
    Skoglund K; Richter J; Olsson-Strömberg U; Bergquist J; Aluthgedara W; Ubhayasekera SJ; Vikingsson S; Svedberg A; Söderlund S; Sandstedt A; Johnsson A; Aagesen J; Alsenhed J; Hägg S; Peterson C; Lotfi K; Gréen H
    Ther Drug Monit; 2016 Apr; 38(2):230-8. PubMed ID: 26693810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
    Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
    Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring.
    Omran MM; Ibrahim AB; Abdelfattah R; Shouman SA; Hamza MS
    Eur J Clin Pharmacol; 2024 Jul; 80(7):1061-1068. PubMed ID: 38536418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.
    Golabchifar AA; Rezaee S; Dinan NM; Kebriaeezadeh A; Rouini MR
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):527-39. PubMed ID: 26189007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application.
    Antunes MV; Raymundo S; Wagner SC; Mattevi VS; Vieira N; Leite R; Reginato F; Capra MZ; Fogliatto L; Linden R
    Bioanalysis; 2015; 7(16):2105-17. PubMed ID: 26327189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
    Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
    J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
    Pfirrmann M; Evtimova D; Saussele S; Castagnetti F; Cervantes F; Janssen J; Hoffmann VS; Gugliotta G; Hehlmann R; Hochhaus A; Hasford J; Baccarani M
    J Cancer Res Clin Oncol; 2017 May; 143(5):843-850. PubMed ID: 28083711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
    Kaygusuz Atagunduz I; Toptas T; Deniz R; Kara O; Eser A; Sezgin A; Ozgumus T; Gecgel F; Firatli Tuglular T
    Clin Lymphoma Myeloma Leuk; 2017 Feb; 17(2):120-125. PubMed ID: 28082113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
    Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK
    Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
    Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.